Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by socio-communicational
deficits and restricted/repetitive behaviors. There is no approved pharmacotherapy
for the treatment of these core symptoms. Cariprazine is an oral dopamine D3-preferring
D3/D2 and serotonin 5-HT1A receptor partial agonist. This study investigated the effects
of cariprazine in a preclinical ASD model.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Published by Elsevier Inc.
